K H Weisgraber
Overview
Explore the profile of K H Weisgraber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
168
Citations
6658
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roses A, Saunders A, Huang Y, Strum J, Weisgraber K, Mahley R
Pharmacogenomics J
. 2006 Jun;
7(1):10-28.
PMID: 16770341
Safety and efficacy pharmacogenetics can be applied successfully to the drug discovery and development pipeline at multiple phases. We review drug-target screening using high throughput SNP associations with complex diseases...
2.
Wilczynski G, Engel W, Strickland D, Weisgraber K, Askanas V
Neurology
. 2002 Feb;
58(3):438-45.
PMID: 11839845
Background: An important aspect of inclusion-body myositis (IBM) vacuolated muscle fibers (VMF) is abnormal accumulation of amyloid-beta precursor protein (AbetaPP) epitopes and its product, amyloid-beta (Abeta), and of phosphorylated tau...
3.
Raffai R, Dong L, Farese Jr R, Weisgraber K
Proc Natl Acad Sci U S A
. 2001 Sep;
98(20):11587-91.
PMID: 11553788
Human apolipoprotein E4 (apoE4) binds preferentially to lower density lipoproteins, including very low density lipoproteins, and is associated with increased risk of atherosclerosis and neurodegenerative disorders, including Alzheimer's disease. This...
4.
Saito H, Dhanasekaran P, Baldwin F, Weisgraber K, Lund-Katz S, Phillips M
J Biol Chem
. 2001 Sep;
276(44):40949-54.
PMID: 11533033
Apolipoprotein (apo) E contains two structural domains, a 22-kDa (amino acids 1-191) N-terminal domain and a 10-kDa (amino acids 223-299) C-terminal domain. To better understand apoE-lipid interactions on lipoprotein surfaces,...
5.
Libeu C, Lund-Katz S, Phillips M, Wehrli S, Hernaiz M, Capila I, et al.
J Biol Chem
. 2001 Aug;
276(42):39138-44.
PMID: 11500500
Defective binding of apolipoprotein E (apoE) to heparan sulfate proteoglycans (HSPGs) is associated with increased risk of atherosclerosis due to inefficient clearance of lipoprotein remnants by the liver. The interaction...
6.
Lund-Katz S, Wehrli S, Zaiou M, Newhouse Y, Weisgraber K, Phillips M
J Lipid Res
. 2001 May;
42(6):894-901.
PMID: 11369796
To understand the molecular basis for the differences in receptor-binding activity of the three common human apolipoprotein E (apoE) isoforms, we characterized the microenvironments of their LDL receptor (LDLR)-binding regions...
7.
Dong J, Weisgraber K, Segelke B, Rupp B, Capila I, Hernaiz M, et al.
Biochemistry
. 2001 Mar;
40(9):2826-34.
PMID: 11258893
Apolipoprotein E (apoE) is an important lipid-transport protein in human plasma and brain. It has three common isoforms (apoE2, apoE3, and apoE4). ApoE is a major genetic risk factor in...
8.
Dong J, Balestra M, Newhouse Y, Weisgraber K
J Lipid Res
. 2000 Nov;
41(11):1783-9.
PMID: 11060347
Apolipoprotein E7 (apoE7) (apoE3 E244K/E245K) is a naturally occurring mutant in humans that is associated with increased plasma lipid levels and accelerated atherosclerosis. It is reported to display defective binding...
9.
Morrow J, SEGALL M, Lund-Katz S, Phillips M, Knapp M, Rupp B, et al.
Biochemistry
. 2000 Sep;
39(38):11657-66.
PMID: 10995233
Denaturation by guanidine-HCl, urea, or heating was performed on the common isoforms of human apolipoprotein (apo) E (apoE2, apoE3, and apoE4) and their 22-kDa and 10-kDa fragments in order to...
10.
Lund-Katz S, Zaiou M, Wehrli S, Dhanasekaran P, Baldwin F, Weisgraber K, et al.
J Biol Chem
. 2000 Aug;
275(44):34459-64.
PMID: 10921925
Lysines in apolipoprotein (apo) E are key factors in the binding of apoE to the low density lipoprotein receptor, and high affinity binding requires that apoE be associated with lipid....